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Cardiac Resynchronization
Therapy in Patients With Narrow QRS
We read with great interest the report by Achilli et al. (1) on
cardiac resynchronization therapy (CRT) in patients with heart
failure (HF) and narrow QRS: the clinical implication of those
data is huge in light of the rapidly expanding indications for CRT.
Achilli et al. (1) described the “long-term” efficacy of CRT in 52
patients (all preselected by echocardiographic recognition of inter-
and intraventricular dyssynchrony) affected by HF, 14 of them
with a QRS 120 ms. Positive results were obtained both from a
clinical and echocardiographic point of view.
The fact that the mean follow-up was 565 days, but that the
“clinical and echocardiographic results” refer to the six-month
follow-up, could be a bit confusing. This may be misleading, and
no doubt the definition of “mid-term” rather than “long-term”
would be more appropriate in describing the follow-up by Achilli
et al. (1).
Our larger experience (158 patients, mean follow-up 1 year) (2),
published just a year before Achilli et al. (1) study (and probably
overlooked by the investigators) also confirms positive results of
CRT in patients with narrow QRS. Based purely on basal QRS
duration, without preselection by any echocardiographic parame-
ter, our patients were defined as wide QRS (150 ms, 128
patients) and narrow QRS (150 ms, 30 patients, 13 with QRS
120 ms, a number comparable to the Achilli et al. [1] narrow
QRS cohort). Our data confirm that, in both groups, CRT
significantly improved clinical and echocardiographic parameters;
in our series these good results were sustained for at least one year.
The most relevant difference between Achilli et al’s. (1) and our
population concerns the mortality rate in the narrow QRS group;
in fact, the 21.4% reported by Achilli et al. (1) in patients with
narrow QRS strongly contrasted with no deaths in our series. In
addition, the mortality rate reported by the investigators was
similar in patients with both narrow and wide QRS duration,
being substantially higher than other reported series.
Finally, we agree that echocardiographic indicators of dyssyn-
chrony can be useful; nonetheless, our data on patients with narrow
QRS have clearly demonstrated that the use of pure “clinical”
selection criteria (i.e., drug refractoriness, severe HF, low ejection
fraction, large diameters) has permitted us to identify patients who
can substantially benefit from CRT in the long term.
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REPLY
We appreciate the interest of Dr. Gasparini and colleagues in our
report (1) and respond to their specific points as follows. First, as
regards our follow-up, we are of the opinion that the definition of
“long-term” is correct considering a mean observation period for
our patient population of 546 days, but clinical and echocardio-
graphic data were collected at 6 months as this reflected the
minimum follow-up for all patients and we believed that this
guaranteed a homogeneous data evaluation. Nevertheless, the
latter definition obviously reflects a “mid-term” follow-up.
Second, we agree that the data published by Gasparini et al. (2)
concur with ours in underscoring the benefit of cardiac resynchro-
nization therapy (CRT) in patients with heart failure and narrow
QRS. However, the definition of a “narrow” QRS is substantially
different in the two studies (110  10 ms vs. 133  15 ms), thus
making the confrontation between patient populations inappropri-
ate as regards the electrical asynchrony profile. Moreover, we
acknowledge with pleasure that 13 patients in the Gasparini et al.
(2) series had a QRS duration 120 ms, but this issue was not
cited in the original report.
The major difference between the two populations is in the
criteria used for the selection of patients. We required the presence
of inter- and intraventricular asynchrony documented by echocar-
diography, whereas the Gasparini et al. (2) patients were selected
solely on the basis of clinical features.
Third, the high mortality rate of our patients might be due to a
disproportionate percentage of New York Heart Association
(NYHA) functional class IV (40%) patients with respect to
previous studies and the absence of functional class II patients in
our study; this is because we had decided, at least in the initial
phase of our experience, to reserve CRT for very ill patients.
Conversely, the subgroup with a narrow QRS from the Gasparini
et al. (2) series included 40% of NYHA functional class II patients.
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